Evidence map›Paper›PMID 35567559›Full record

Trial reportEuropean heart journal2022

Bone marrow activation in response to metabolic syndrome and early atherosclerosis.

Ana Devesa, Manuel Lobo-González, Juan Martínez-Milla, Belén Oliva, Inés García-Lunar, Annalaura Mastrangelo, Samuel España, Javier Sanz, José M Mendiguren, Hector Bueno and 9 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01410318 (Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors), which is not on this map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01410318 active not recruitingnot on this map

Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors

TypeobservationalSponsorFundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIRan2010 to 2030Enrolled4,184ConditionsAtherosclerosis
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. [EJNMMI research · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Can Nuclear Imaging Detect Trained Immunity in Cardiovascular Disease?Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Role of Trained Immunity in Heath and Disease.Current cardiology reports · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Ana DevesaCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0001-5981-2546
Manuel Lobo-GonzálezCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Juan Martínez-MillaCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Belén OlivaCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0001-6352-5574
Inés García-LunarCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0003-4117-6814
Annalaura MastrangeloCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0003-2650-0444
Samuel EspañaCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0001-9092-4597
Javier SanzCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
José M MendigurenBanco de Santander, Madrid, Spain.
Hector BuenoCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Jose J FusterCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0002-5970-629X
Vicente AndrésCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0002-0125-7209
Antonio Fernández-OrtizCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0002-3239-1910
David SanchoCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0003-2890-3984
Leticia Fernández-FrieraCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Javier Sanchez-GonzalezPhilips Healthcare, Madrid, Spain.ORCID 0000-0003-1427-3870
Xavier RosselloCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0001-6783-8463
Borja IbanezCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0002-5036-254X
Valentin FusterCentro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.ORCID 0000-0002-9043-9986
Spanish National Centre for Cardiovascular Research · ESBanco Santander (Spain) · ESPhilips (Spain) · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsExperimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. METHODS AND

resultsWhole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8-53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3-L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis-characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts-and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden).

conclusionIn apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development.[Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].

Indexed as

AtherosclerosisMetabolic SyndromePlaque, AtheroscleroticBiomarkersBone MarrowFemaleFluorodeoxyglucose F18HumansInflammationMaleMiddle AgedPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsBiomarkersFluorodeoxyglucose F18RadiopharmaceuticalsBone marrowMetabolic syndromePET/MRISubclinical atherosclerosis

Identifiers

PMID35567559
PMCPMC9113301
OpenAlexW4220998065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.